BeiGene Q2 EPADS $(3.64) Misses $(2.81) Estimate, Sales $595.26M Beat $519.08M Estimate
Portfolio Pulse from Benzinga Newsdesk
BeiGene reported Q2 losses of $3.64 per share, missing the analyst consensus estimate of $2.81 by 29.54%. However, the company's quarterly sales of $595.26 million beat the analyst consensus estimate of $519.08 million by 14.68%. This represents a 74.27% increase over sales from the same period last year.
August 04, 2023 | 10:46 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BeiGene's Q2 earnings per share missed estimates, but sales exceeded expectations and showed significant year-over-year growth.
While BeiGene's earnings per share missed estimates, which could negatively impact the stock, the company's strong sales performance and significant year-over-year growth could offset this and have a positive impact. Therefore, the overall short-term impact on the stock is expected to be neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100